$2.20
3.08% yesterday
Nasdaq, Jul 03, 06:57 pm CET
ISIN
US55028X1090
Symbol
LUMO
Sector
Industry

Lumos Pharma Inc Share price

$2.20
-0.10 4.35% 1M
-0.86 28.10% 6M
-0.98 30.82% YTD
-0.98 30.84% 1Y
-8.00 78.43% 3Y
-10.76 83.02% 5Y
-248.54 99.12% 10Y
Nasdaq, Closing price Wed, Jul 03 2024
-0.07 3.08%
ISIN
US55028X1090
Symbol
LUMO
Sector
Industry

Key metrics

Market capitalization $17.86m
Enterprise Value $1.20m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.78
P/S ratio (TTM) P/S ratio 11.67
P/B ratio (TTM) P/B ratio 1.02
Sales growth (TTM) Sales growth -27.48%
Turnover (TTM) Turnover $1.53m
EBIT (operating result TTM) EBIT $-39.44m
Free cash flow (TTM) Free cash flow $-32.33m
Cash position $23.18m
EPS (TTM) EPS $-4.59
P/E ratio expected negative
P/S ratio expected 1.28
EV/Sales expected 0.09
Short interest 5.21%
Show more

Is Lumos Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

Lumos Pharma Inc Share analysis

Unlock Scores for Free

Analyst opinions

3 Analysts have issued a Lumos Pharma Inc forecast:

3x Buy
100%

Analyst opinions

3 Analysts have issued a Lumos Pharma Inc forecast:

Buy
100%

Financial data from Lumos Pharma Inc

Assets
Dec '23
40 40
Cash position 36 36
Claims 0.21 0.21
Inventories - -
Other current assets Other current assets Current assets 3.75 3.75
0.60 0.60
Property, plant and equipment 0.60 0.60
Financial assets - -
Intangible assets - -
Other fixed assets Other assets Fixed assets - -
Total assets 41 41
Liabilities
Dec '23
Equity 27 27
13 13
Current liabilities 7.03 7.03
Non-current liabilities 6.30 6.30
Total capital 41 41

Figures in millions USD.

Don't miss a thing! We will send you all news about the Lumos Pharma Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Lumos Pharma Inc Share News

Neutral
GlobeNewsWire
about one month ago
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO) , to be held i...
Neutral
Seeking Alpha
about 2 months ago
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Officer & Chairman John McKew - President & Chief Scientific Officer Lori Lawley - Chief Financial Officer Duke Pitukcheewanont - Chief Medical Officer Conference Call Participants Liam Hiester - Piper San...
Neutral
GlobeNewsWire
about 2 months ago
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma,...
More Lumos Pharma Inc News

Company profile

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Head office United States
CEO Richard Hawkins
Employees 33
Founded 1999
Website www.lumos-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today